TuHURA Biosciences is a clinical-stage immuno-oncology company developing novel therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company's lead program, IFx-2.0, uses an innate immune agonist technology designed to make tumors appear foreign to the immune system, enabling patients to respond to checkpoint inhibitors; additional candidates include a VISTA inhibitor monoclonal antibody for acute myeloid leukemia and bi-specific antibody-drug conjugates targeting myeloid-derived suppressor cells. The company generates value through partnerships with larger pharmaceutical companies providing non-dilutive capital, licenses intellectual property in the low-to-mid single-digit royalty range, and employs contract manufacturers and external partners to reduce capital requirements while advancing products through accelerated regulatory pathways.